Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
05 January 2024 - 8:05AM
Business Wire
Novocure (NASDAQ: NVCR) today announced the appointment of
Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical
Officer. Dr. Leupin brings a proven track record of leadership and
accomplishment in the biotechnology and pharmaceutical industries,
as well as extensive experience as a medical oncologist and
educator. At Novocure, Dr. Leupin will oversee medical affairs,
medical safety, and clinical development operations as the company
advances its clinical pipeline and prepares to treat an expanded
patient population.
“It is a pleasure to welcome Dr. Leupin to Novocure as our new
Chief Medical Officer,” said Asaf Danziger, Novocure’s Chief
Executive Officer. “Nicolas brings a wealth of knowledge and
experience from some of the most innovative oncology companies in
the world, as well as a dedication to patients that is core to
Novocure’s mission. I am confident that his expertise will be
instrumental as Novocure enters its next chapter, treating patients
with aggressive tumors of the brain, torso and abdomen.”
“I am thrilled to join Novocure’s executive leadership team and
contribute to the innovation and expansion of this novel modality,
Tumor Treating Fields therapy,” said Dr. Leupin. “2024 is a
critical year for Novocure with multiple opportunities on the
horizon and I am excited to be joining a company with such strong
capabilities and aspirations to materially advance patient
care.”
Before joining Novocure, Dr. Leupin served as the Chief Medical
Officer at Molecular Partners, a clinical-stage biopharmaceutical
company, where he led the development of multiple designed ankyrin
repeat protein therapeutics. Prior to his time at Molecular
Partners, Dr. Leupin served as the Chief Medical Officer at Argenx,
a leader in the development of therapeutic antibodies, and was
instrumental in the development of Vyvgart and other compounds.
Before moving into executive leadership, Dr. Leupin held a number
of clinical development leadership roles at Celgene in the myeloma
and lymphoma programs.
Dr. Leupin earned his M.D. at the University of Bern, his Ph.D.
from the UBFC-Université in France, and an MBA from Jones
International University in the U.S. Dr. Leupin is a board
certified medical oncologist with a specialty in hematological
oncology. He has co-authored high-impact papers in peer-reviewed
scientific journals, and is dedicated to educating the generation
of oncologists through his continuing work as a lecturer of Tumor
Biology at the University of Bern.
Dr. Leupin will assume the clinical and medical responsibilities
held by Pritesh Shah, Novocure’s former Chief Growth Officer. As
previously announced, Mr. Shah resigned his position as an
executive officer effective January 1, 2024 and has agreed to
become a Senior Advisor to the Chief Executive Officer in a
non-executive capacity.
“I would like to thank Pritesh for his dedication and leadership
over the 12 years,” said Asaf Danziger. “Pritesh has been at
Novocure since the beginning of our commercial business and helped
shape and build our business from scratch. I am very grateful to
Pritesh and wish him a lifetime of happiness.”
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma, malignant pleural mesothelioma and pleural
mesothelioma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in brain metastases, gastric
cancer, glioblastoma, liver cancer, non-small cell lung cancer,
pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical study progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions as well as issues arising from the COVID-19
pandemic and other more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2023, and subsequent filings with the U.S.
Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such
factors or forward-looking statements. Furthermore, Novocure does
not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak
only as of the date hereof. The Private Securities Litigation
Reform Act of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240104337946/en/
Investors & Media: Ingrid Goldberg 610-723-7427
investorinfo@novocure.com media@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2024 to May 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From May 2023 to May 2024